###begin article-title 0
###xml 122 126 <span type="species:ncbi:10090">mice</span>
Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice
###end article-title 0
###begin p 1
###xml 1911 1914 1911 1914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1943 1946 1943 1946 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
###xml 148 163 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 592 597 <span type="species:ncbi:10090">mouse</span>
###xml 759 763 <span type="species:ncbi:10090">mice</span>
###xml 843 848 <span type="species:ncbi:10090">mouse</span>
###xml 1004 1008 <span type="species:ncbi:10090">mice</span>
###xml 1741 1746 <span type="species:ncbi:9606">human</span>
###xml 1915 1919 <span type="species:ncbi:10090">mice</span>
###xml 1947 1951 <span type="species:ncbi:10090">mice</span>
The ability to genetically manipulate mice has led to rapid progress in our understanding of the roles of different gene products in human disease. Transgenic mice have often been created in the FVB/NJ (FVB) strain due to its high fecundity, while gene-targeted mice have been developed in the 129/SvJ-C57Bl/6J strains due to the capacity of 129/SvJ embryonic stem cells to facilitate germline transmission. Gene-targeted mice are commonly backcrossed into the C57Bl/6J (B6) background for comparison with existing data. Genetic modifiers have been shown to modulate mammary tumor latency in mouse models of breast cancer and it is commonly known that the FVB strain is susceptible to mammary tumors while the B6 strain is more resistant. Since gene-targeted mice in the B6 background are frequently bred into the polyomavirus middle T (PyMT) mouse model of breast cancer in the FVB strain, we have sought to understand the impact of the different genetic backgrounds on the resulting phenotype. We bred mice deficient in the inducible nitric oxide synthase (iNOS) until they were congenic in the PyMT model in the FVB and B6 strains. Our results reveal that the large difference in mean tumor latencies in the two backgrounds of 53 and 92 days respectively affect the ability to discern smaller differences in latency due to the Nos2 genetic mutation. Furthermore, the longer latency in the B6 strain enables a more detailed analysis of tumor formation indicating that individual tumor development is not stoichastic, but is initiated in the #1 glands and proceeds in early and late phases. NO production affects tumors that develop early suggesting an association of iNOS-induced NO with a more aggressive tumor phenotype, consistent with human clinical data positively correlating iNOS expression with breast cancer progression. An examination of lung metastases, which are significantly reduced in PyMT/iNOS-/- mice compared with PyMT/iNOS+/+ mice only in the B6 background, is concordant with these findings. Our data suggest that PyMT in the B6 background provides a useful model for the study of inflammation-induced breast cancer.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2003</xref>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2003</xref>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">1999</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2002</xref>
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 306 331 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 354 358 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 467 472 <span type="species:ncbi:9606">human</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
Transgenic mouse models that develop spontaneous mammary adenocarcinomas have proven valuable in revealing molecular mechanisms underlying tumorigenesis and metastasis (Cardiff 2003; Fargiano et al. 2003). Models target specific pathways depending on the transgene being expressed under the control of the mouse mammary tumor virus long terminal repeat (MMTV-LTR) or whey acid protein (WAP) mammary gland promoters and thereby replicate genetic defects in subsets of human tumors (Cardiff and Wellings 1999; Rosner et al. 2002). Molecules from pathways known to be important in the pathogenesis of human breast cancer such as the Wnt, Ras and ErbB2/Neu pathways have been utilized, however few spontaneous mammary tumor model systems develop metastasis, a crucial aspect of cancer progression.
###end p 4
###begin p 5
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2003</xref>
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1992</xref>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">2004</xref>
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2003</xref>
###xml 801 805 801 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1994</xref>
###xml 818 822 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2001</xref>
###xml 839 843 839 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">1998</xref>
###xml 861 865 861 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2004</xref>
###xml 1218 1222 1218 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2000</xref>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 646 651 <span type="species:ncbi:9606">human</span>
###xml 871 876 <span type="species:ncbi:9606">women</span>
###xml 1325 1330 <span type="species:ncbi:9606">human</span>
As demonstrated by gene expression analysis (Ma et al. 2003), the polyomavirus middle T (PyMT) model in the FVB/N (FVB) background activates the same signaling pathways as erbB2, an oncogene amplified or overexpressed in approximately 30% of human breast cancers. The model has been particularly useful for genetic studies due to its short tumor latency and high incidence of pulmonary metastasis (Guy et al. 1992). These features have enabled global expression profiling of PyMT tumors from different genetic backgrounds to identify signatures of tumor virulence (Qiu et al. 2004) that are consistent with a gene set predictive of metastasis in human tumors (Ramaswamy et al. 2003). Hence, the model has been used effectively to dissect early and late stages of mammary tumor development (Guy et al. 1994; Lin et al. 2001; Webster et al. 1998; Williams et al. 2004). In women with breast cancers involving this pathway, the course of the disease varies widely. One powerful means to understand that variability is to identify useful animal models. The PyMT breast cancer model can be used in genetic crossing experiments to identify loci having modifier effects on either tumorigenesis or metastasis (Le Voyer et al. 2000). An understanding of the genetic polymorphisms underlying these effects is important in the study of human cancer as genetic variability affects host-tumor interactions in numerous ways and is an important factor in the response to therapy.
###end p 5
###begin p 6
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1992</xref>
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">1983</xref>
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">1967</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">1965</xref>
###xml 442 443 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">k</sup>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1992</xref>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">q</sup>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1992</xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Widely varied tumor responses to polyoma virus infection among different inbred strains of mice have been well documented (Freund et al. 1992; Gross 1983). Much of this difference can be attributed to the major histocompatibility complex (MHC) which results in immunologically mediated resistance associated with an H-2b haplotype such as in C57Bl strains (Law et al. 1967; Ting and Law 1965). Other inbred strains, notably those with the H-2d and H-2k haplotypes have moderate and weak tumor resistance respectively (Freund et al. 1992). The FVB strain has an H-2q haplotype, which may be an additional MHC locus that confers susceptibility to polyoma virus induced tumorigenesis. Alternatively, non-MHC genes can also result in a dominant pattern of tumor susceptibility as in the case of the C3H/BiDa strain (Freund et al. 1992).
###end p 6
###begin p 7
###xml 527 531 527 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">1998</xref>
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Strain variations are also relevant to the study of genetic mutations in mouse models of disease. An analysis of targeted disruptions on mammary tumorigenesis in the PyMT model requires breeding of knockout models usually developed in the 129/SvJ-C57Bl/6J background into the FVB background. It is commonly recognized that the FVB strain is susceptible while the C57Bl/6J (B6) strain is more resistant to PyMT mammary tumorigenesis and F1 crosses of these strains increase tumor latency by approximately 6 days (Lifsted et al. 1998). However, it is not clear what effects continued backcrossing has on the analysis of targeted mutations in the PyMT model.
###end p 7
###begin p 8
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2003</xref>
###xml 297 302 <span type="species:ncbi:10090">mouse</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
Previously we reported that inducible nitric oxide synthase (iNOS) deficiency in the PyMT model in the B6 background resulted in an increase in tumor latency that was not observed in the FVB background (Ellies et al. 2003). Since the issue of strain background is an important one for analysis of mouse models we have made iNOS knockout mice congenic in the FVB and B6 backgrounds and carried out a comparison of tumorigenesis and metastasis in both strains.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
Animals
###end title 10
###begin p 11
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1992</xref>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm1Lau</italic>
###xml 305 311 305 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm1Lau</italic></sup>
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">1995</xref>
###xml 497 500 497 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 511 514 511 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 835 839 835 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 839 845 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm1Lau</italic>
###xml 839 845 839 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm1Lau</italic></sup>
###xml 847 850 847 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 865 868 865 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nos2</italic>
###xml 914 920 914 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm1Lau</italic>
###xml 914 920 914 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm1Lau</italic></sup>
###xml 922 925 922 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 940 943 940 943 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1224 1225 1224 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 15 19 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 807 811 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 851 855 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
###xml 1310 1314 <span type="species:ncbi:10090">mice</span>
PyMT (FVB/N-Tg(MMTV-PyVT)634Mul/J) mice (Guy et al. 1992) were obtained from W. Muller (McMaster University, Ontario, Canada). We acquired PyMT mice that had been backcrossed 5 generations into the B6 background from A. Varki (UCSD, La Jolla, CA). Control (C57Bl/6J) and iNOS deficient mice (B6.129P2-Nos2tm1Lau/J; Laubach et al. 1995) were purchased from The Jackson Laboratory, Bar Harbor, ME. The PyMT B6 mice were further backcrossed until congenic in the B6 background and then bred with iNOS-/- mice. iNOS-/- mice were bred into the FVB background until congenic (>10 generations) and then crossed with PyMT FVB mice. Female mice heterozygous for the PyMT transgene and homozygous for the wild type or mutated iNOS gene were used in these studies. For clarity and brevity, we have designated FVB/N-Tg(MMTV-PyVT)634Mul/JxB6.129P2-Nos2tm1Lau/J+/+ mice PyMT/iNOS+/+ and FVB/N-Tg(MMTV-PyVT)634Mul/JxB6.129P2-Nos2tm1Lau/J-/- mice PyMT/iNOS-/-. FVB mice were palpated twice weekly from 4 weeks of age and B6 mice once weekly from 8 weeks of age to monitor mammary tumor development. Tumors were measured in 2 dimensions using calipers and tumor volume estimated using the standard calculation for a sphere 4/3 x 3.14 x a x b2 where a is the smaller diameter and b is the larger diameter. After euthanizing the mice, mammary tumors were dissected and weighed and the total tumor burden calculated (tumor weight/body weight). All studies followed the NIH guidelines for the care and treatment of experimental laboratory rodents.
###end p 11
###begin title 12
Mammary gland whole mounts
###end title 12
###begin p 13
Pairs of inguinal mammary glands were fixed in formalin or Carnoy's fixative, dehydrated through a graded series of ethanol solutions and defatted in xylene. Following rehydration, the mammary epithelium was stained with carmine stain (Sigma Chemical, St Louis, MO) for 30 min. After removing excess stain by washing in water, samples were dehydrated and stored in methyl salicylate (Sigma Chemical, St Louis, MO).
###end p 13
###begin title 14
Tumor microvascular density
###end title 14
###begin p 15
###xml 176 180 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2003</xref>
###xml 466 467 465 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Cryosections of OCT embedded tumor samples were cut at 7 mum and stained with anti-CD31 clone 13.3 (1:200, BD Pharmingen, San Diego, CA) as previously described (Ellies et al. 2003). Five random fields per tumor were captured on the Spot RT digital camera system (Diagnostic Instruments, Sterling Heights, MI) at 200x magnification and analyzed using the public domain NIH Image program (http://rsb.info.nih.gov/nih-image/). Microvessel areas were normalized to 1 mm2 of epithelium.
###end p 15
###begin title 16
Lung metastases
###end title 16
###begin p 17
###xml 334 335 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 357 358 357 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 463 466 462 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 479 482 478 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
Paraffin embedded lungs were serial sectioned and stained with hematoxylin and eosin. Both the numbers and areas of lung metastases were measured by light microscopy using images and software from the Spot RT digital camera system. Lung area per section was measured using a dissecting scope and metastatic tumor burden calculated (mm2 of lung metastases/cm2 of lung tissue) for each animal using data from 3 sections at least 100 mum apart. At least 13 PyMT/iNOS+/+ or PyMT/iNOS-/- mice were used in this analysis.
###end p 17
###begin title 18
Statistical analysis
###end title 18
###begin p 19
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 357 358 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 419 422 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 436 439 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
The percentage of mice tumor free in each group was analyzed using a Kaplan-Meier survival analysis, and the log-rank statistic was used for comparison of the curves between groups. The t-test was used for comparison of 2 groups and the analysis of variance (ANOVA) followed by the Bonferroni post-test was applied to multiple comparisons. The Mann-Whitney U test was used to compare metastastic burden in the PyMT/iNOS+/+ and PyMT/iNOS-/- groups.
###end p 19
###begin title 20
Results
###end title 20
###begin title 21
PyMT tumorigenesis is delayed in the C57Bl/6 strain
###end title 21
###begin p 22
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">1992</xref>
###xml 542 543 542 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 696 697 696 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 701 707 701 707 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1</label>
###xml 754 755 754 755 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 956 957 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 986 986 986 986 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f40490"/>
###xml 996 997 996 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1004 1004 1004 1004 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f40550"/>
###xml 1012 1013 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1021 1022 1021 1022 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1080 1083 1080 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 707 1141 707 1141 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">PyMT tumorigenesis in the FVB and B6 strains. (<bold>A</bold>) The day at which the first mammary tumor was detected by palpation in each mouse was recorded and a Kaplan-Meier survival plot generated. Log rank analysis indicated a highly significant difference, <italic>P</italic>&#160;&lt;&#160;0.001 between the curves. <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f40490"/> FVB mice <italic>N</italic>&#160;=&#160;44, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f40550"/>B6 mice <italic>N</italic>&#160;=&#160;46. (<bold>B</bold>) Whole mounts of mammary glands from 3&#160;week old PyMT/iNOS<sup>+/+</sup> mice of the FVB (left panel) and B6 (right panel) strains</p>
###xml 707 1141 707 1141 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">PyMT tumorigenesis in the FVB and B6 strains. (<bold>A</bold>) The day at which the first mammary tumor was detected by palpation in each mouse was recorded and a Kaplan-Meier survival plot generated. Log rank analysis indicated a highly significant difference, <italic>P</italic>&#160;&lt;&#160;0.001 between the curves. <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f40490"/> FVB mice <italic>N</italic>&#160;=&#160;44, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f40550"/>B6 mice <italic>N</italic>&#160;=&#160;46. (<bold>B</bold>) Whole mounts of mammary glands from 3&#160;week old PyMT/iNOS<sup>+/+</sup> mice of the FVB (left panel) and B6 (right panel) strains</p></caption>
###xml 1141 1141 1141 1141 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11248_2006_9056_Fig1_HTML" id="MO1"/>
###xml 701 1141 701 1141 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig. 1</label><caption><p textid="23">PyMT tumorigenesis in the FVB and B6 strains. (<bold>A</bold>) The day at which the first mammary tumor was detected by palpation in each mouse was recorded and a Kaplan-Meier survival plot generated. Log rank analysis indicated a highly significant difference, <italic>P</italic>&#160;&lt;&#160;0.001 between the curves. <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f40490"/> FVB mice <italic>N</italic>&#160;=&#160;44, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f40550"/>B6 mice <italic>N</italic>&#160;=&#160;46. (<bold>B</bold>) Whole mounts of mammary glands from 3&#160;week old PyMT/iNOS<sup>+/+</sup> mice of the FVB (left panel) and B6 (right panel) strains</p></caption><graphic position="anchor" xlink:href="11248_2006_9056_Fig1_HTML" id="MO1"/></fig>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
###xml 497 501 <span type="species:ncbi:10090">mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
###xml 832 837 <span type="species:ncbi:10090">mouse</span>
###xml 991 995 <span type="species:ncbi:10090">mice</span>
###xml 1007 1011 <span type="species:ncbi:10090">mice</span>
###xml 1084 1088 <span type="species:ncbi:10090">mice</span>
The PyMT model was originally developed in the FVB strain due to its high fecundity. Tumor growth occurs rapidly and metastatic tumors form in the lungs (Guy et al. 1992). To compare tumorigenesis in the FVB strain with that in the C57Bl/6 strain onto which many genetically modified strains are bred, we made PyMT mice congenic in the B6 background. Examination of tumor latency showed a dramatic difference with a mean latency of 53 days for PyMT tumor development in FVB mice and 92 days in B6 mice, a delay of approximately 6 weeks (Fig. 1A). Whole mounts of mammary glands from the two strains also showed that even at weaning, hyperplasias were more advanced in FVB than B6 PyMT mice (Fig. 1B). Fig. 1PyMT tumorigenesis in the FVB and B6 strains. (A) The day at which the first mammary tumor was detected by palpation in each mouse was recorded and a Kaplan-Meier survival plot generated. Log rank analysis indicated a highly significant difference, P < 0.001 between the curves.  FVB mice N = 44, B6 mice N = 46. (B) Whole mounts of mammary glands from 3 week old PyMT/iNOS+/+ mice of the FVB (left panel) and B6 (right panel) strains
###end p 22
###begin p 23
###xml 47 48 47 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 279 279 279 279 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f40490"/>
###xml 289 290 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 297 297 297 297 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f40550"/>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 314 315 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 373 376 373 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 125 130 <span type="species:ncbi:10090">mouse</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 377 381 <span type="species:ncbi:10090">mice</span>
PyMT tumorigenesis in the FVB and B6 strains. (A) The day at which the first mammary tumor was detected by palpation in each mouse was recorded and a Kaplan-Meier survival plot generated. Log rank analysis indicated a highly significant difference, P < 0.001 between the curves.  FVB mice N = 44, B6 mice N = 46. (B) Whole mounts of mammary glands from 3 week old PyMT/iNOS+/+ mice of the FVB (left panel) and B6 (right panel) strains
###end p 23
###begin title 24
Effects of iNOS deficiency are more apparent in the C57Bl/6 background
###end title 24
###begin p 25
###xml 154 157 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2003</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 609 610 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 614 620 614 620 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 678 679 678 679 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 706 709 706 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 723 726 723 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 805 806 805 806 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 860 863 860 863 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 878 881 878 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 946 946 946 946 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figc_HTML.gif" id="N0x1d43c40N0x2f75db0"/>
###xml 955 958 955 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 963 964 963 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 971 971 971 971 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f75e70"/>
###xml 980 983 980 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 988 989 988 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 996 996 996 996 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f75f30"/>
###xml 1005 1008 1005 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1012 1013 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1020 1020 1020 1020 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f75ff0"/>
###xml 1029 1032 1029 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1036 1037 1036 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 620 1042 620 1042 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Effects of iNOS deficiency on mammary tumor development. (<bold>A</bold>) Whole mounts of PyMT/iNOS<sup>+/+</sup> and PyMT/iNOS<sup>&#8722;/&#8722;</sup> #4 mammary glands from 11&#160;week FVB mice or 20&#160;week B6 mice. LN = lymph node. (<bold>B</bold>) Kaplan Meier plots of the tumor latency of PyMT/iNOS<sup>+/+</sup> annd PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice of the 2 strains. Data were analyzed by the log rank test. <inline-graphic xlink:href="11248_2006_9056_Figc_HTML.gif" id="N0x1d43c40N0x2f75db0"/>PyMT/iNOS<sup>+/+</sup> FVB <italic>N</italic>&#160;=&#160;44, <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f75e70"/>PyMT/iNOS<sup>&#8722;/&#8722;</sup> FVB <italic>N</italic>&#160;=&#160;57, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f75f30"/>PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;46, <inline-graphic xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f75ff0"/>PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;26</p>
###xml 620 1042 620 1042 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Effects of iNOS deficiency on mammary tumor development. (<bold>A</bold>) Whole mounts of PyMT/iNOS<sup>+/+</sup> and PyMT/iNOS<sup>&#8722;/&#8722;</sup> #4 mammary glands from 11&#160;week FVB mice or 20&#160;week B6 mice. LN = lymph node. (<bold>B</bold>) Kaplan Meier plots of the tumor latency of PyMT/iNOS<sup>+/+</sup> annd PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice of the 2 strains. Data were analyzed by the log rank test. <inline-graphic xlink:href="11248_2006_9056_Figc_HTML.gif" id="N0x1d43c40N0x2f75db0"/>PyMT/iNOS<sup>+/+</sup> FVB <italic>N</italic>&#160;=&#160;44, <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f75e70"/>PyMT/iNOS<sup>&#8722;/&#8722;</sup> FVB <italic>N</italic>&#160;=&#160;57, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f75f30"/>PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;46, <inline-graphic xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f75ff0"/>PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;26</p></caption>
###xml 1042 1042 1042 1042 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11248_2006_9056_Fig2_HTML" id="MO2"/>
###xml 614 1042 614 1042 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="26">Effects of iNOS deficiency on mammary tumor development. (<bold>A</bold>) Whole mounts of PyMT/iNOS<sup>+/+</sup> and PyMT/iNOS<sup>&#8722;/&#8722;</sup> #4 mammary glands from 11&#160;week FVB mice or 20&#160;week B6 mice. LN = lymph node. (<bold>B</bold>) Kaplan Meier plots of the tumor latency of PyMT/iNOS<sup>+/+</sup> annd PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice of the 2 strains. Data were analyzed by the log rank test. <inline-graphic xlink:href="11248_2006_9056_Figc_HTML.gif" id="N0x1d43c40N0x2f75db0"/>PyMT/iNOS<sup>+/+</sup> FVB <italic>N</italic>&#160;=&#160;44, <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f75e70"/>PyMT/iNOS<sup>&#8722;/&#8722;</sup> FVB <italic>N</italic>&#160;=&#160;57, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f75f30"/>PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;46, <inline-graphic xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f75ff0"/>PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;26</p></caption><graphic position="anchor" xlink:href="11248_2006_9056_Fig2_HTML" id="MO2"/></fig>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 158 162 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
###xml 781 785 <span type="species:ncbi:10090">mice</span>
###xml 882 886 <span type="species:ncbi:10090">mice</span>
To determine how this difference in tumor latency may affect the phenotype observed following crossbreeding with genetically altered mice, we bred in iNOS-/- mice congenic in the two backgrounds. As previously reported, we observed a 3-4 week delay in palpable tumors in B6 PyMT mice lacking iNOS activity (Ellies et al. 2003). However, this difference was difficult to discern in the FVB background due to the rapid tumor onset (Fig. 2A). Mammary gland whole mounts reflected the latency data with a clear difference in tumor growth with iNOS deficiency being observed in the #4 glands of B6 PyMT mice (Fig. 2A). Fig. 2Effects of iNOS deficiency on mammary tumor development. (A) Whole mounts of PyMT/iNOS+/+ and PyMT/iNOS-/- #4 mammary glands from 11 week FVB mice or 20 week B6 mice. LN = lymph node. (B) Kaplan Meier plots of the tumor latency of PyMT/iNOS+/+ annd PyMT/iNOS-/- mice of the 2 strains. Data were analyzed by the log rank test. PyMT/iNOS+/+ FVB N = 44, PyMT/iNOS-/- FVB N = 57, PyMT/iNOS+/+ B6 N = 46, PyMT/iNOS-/- B6 N = 26
###end p 25
###begin p 26
###xml 58 59 58 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 103 106 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 185 186 185 186 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 240 243 240 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 258 261 258 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 326 326 326 326 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figc_HTML.gif" id="N0x1d43c40N0x2f75db0"/>
###xml 335 338 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 343 344 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 351 351 351 351 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f75e70"/>
###xml 360 363 360 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 376 376 376 376 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f75f30"/>
###xml 385 388 385 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 400 400 400 400 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f75ff0"/>
###xml 409 412 409 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 416 417 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
###xml 262 266 <span type="species:ncbi:10090">mice</span>
Effects of iNOS deficiency on mammary tumor development. (A) Whole mounts of PyMT/iNOS+/+ and PyMT/iNOS-/- #4 mammary glands from 11 week FVB mice or 20 week B6 mice. LN = lymph node. (B) Kaplan Meier plots of the tumor latency of PyMT/iNOS+/+ annd PyMT/iNOS-/- mice of the 2 strains. Data were analyzed by the log rank test. PyMT/iNOS+/+ FVB N = 44, PyMT/iNOS-/- FVB N = 57, PyMT/iNOS+/+ B6 N = 46, PyMT/iNOS-/- B6 N = 26
###end p 26
###begin title 27
PyMT tumor growth kinetics vary in FVB/N and C57Bl/6 strains
###end title 27
###begin p 28
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 706 707 706 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 810 816 810 816 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 848 849 848 849 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 880 880 880 880 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f763b0"/>
###xml 884 885 884 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 892 892 892 892 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76470"/>
###xml 895 896 895 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 928 929 926 927 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 972 975 970 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 989 992 987 990 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1050 1053 1048 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1053 1053 1051 1051 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76590"/>
###xml 1070 1073 1068 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1073 1073 1071 1071 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f765f0"/>
###xml 816 1079 816 1077 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Mammary tumor growth kinetics. (<bold>A</bold>) Mean tumor volume per mouse. <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f763b0"/>FVB <italic>N</italic>&#160;=&#160;32, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76470"/>B6 <italic>N</italic>&#160;=&#160;44. Data are means&#160;&#177;&#160;SEM. (<bold>B</bold>) Tumor latency for individual B6 PyMT/iNOS<sup>+/+</sup> and PyMT/iNOS<sup>&#8722;/&#8722;</sup> tumors. Data were derived from examining 460 B6 PyMT/iNOS<sup>+/+</sup><inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76590"/>and 260 PyMT/iNOS<sup>&#8722;/&#8722;</sup><inline-graphic xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f765f0"/>tumors</p>
###xml 816 1079 816 1077 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Mammary tumor growth kinetics. (<bold>A</bold>) Mean tumor volume per mouse. <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f763b0"/>FVB <italic>N</italic>&#160;=&#160;32, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76470"/>B6 <italic>N</italic>&#160;=&#160;44. Data are means&#160;&#177;&#160;SEM. (<bold>B</bold>) Tumor latency for individual B6 PyMT/iNOS<sup>+/+</sup> and PyMT/iNOS<sup>&#8722;/&#8722;</sup> tumors. Data were derived from examining 460 B6 PyMT/iNOS<sup>+/+</sup><inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76590"/>and 260 PyMT/iNOS<sup>&#8722;/&#8722;</sup><inline-graphic xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f765f0"/>tumors</p></caption>
###xml 1079 1079 1077 1077 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11248_2006_9056_Fig3_HTML" id="MO3"/>
###xml 810 1079 810 1077 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="29">Mammary tumor growth kinetics. (<bold>A</bold>) Mean tumor volume per mouse. <inline-graphic xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f763b0"/>FVB <italic>N</italic>&#160;=&#160;32, <inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76470"/>B6 <italic>N</italic>&#160;=&#160;44. Data are means&#160;&#177;&#160;SEM. (<bold>B</bold>) Tumor latency for individual B6 PyMT/iNOS<sup>+/+</sup> and PyMT/iNOS<sup>&#8722;/&#8722;</sup> tumors. Data were derived from examining 460 B6 PyMT/iNOS<sup>+/+</sup><inline-graphic xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76590"/>and 260 PyMT/iNOS<sup>&#8722;/&#8722;</sup><inline-graphic xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f765f0"/>tumors</p></caption><graphic position="anchor" xlink:href="11248_2006_9056_Fig3_HTML" id="MO3"/></fig>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 873 878 <span type="species:ncbi:10090">mouse</span>
The pattern of tumor growth differed between strains and may in part account for the greater disparity in tumor development observed in the absence of iNOS in PyMT B6 mice. Once the mean tumor volume reached 1 cm3, tumor growth proceeded exponentially in the PyMT FVB mice leading to sacrifice within 3 weeks (Fig. 3A). To achieve the same final tumor volume, the PyMT B6 mice required approximately 7 weeks and growth followed a more linear pattern, suggesting more variable rates of growth of individual tumors. Indeed, when we analyzed the tumor latency of all tumors, we were able to define two distinct phases of tumor growth in the B6 strain: early, from 12-17 weeks and late, from 19-23 weeks (Fig. 3B). The major effect of iNOS deficiency appears to be a delay in the early phase of tumor development. Fig. 3Mammary tumor growth kinetics. (A) Mean tumor volume per mouse. FVB N = 32, B6 N = 44. Data are means +/- SEM. (B) Tumor latency for individual B6 PyMT/iNOS+/+ and PyMT/iNOS-/- tumors. Data were derived from examining 460 B6 PyMT/iNOS+/+and 260 PyMT/iNOS-/-tumors
###end p 28
###begin p 29
###xml 32 33 32 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 64 64 64 64 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figa_HTML.gif" id="N0x1d43c40N0x2f763b0"/>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 76 76 76 76 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76470"/>
###xml 79 80 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 112 113 110 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 156 159 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 173 176 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 234 237 232 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 237 237 235 235 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figb_HTML.gif" id="N0x1d43c40N0x2f76590"/>
###xml 254 257 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 257 257 255 255 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11248_2006_9056_Figd_HTML.gif" id="N0x1d43c40N0x2f765f0"/>
###xml 57 62 <span type="species:ncbi:10090">mouse</span>
Mammary tumor growth kinetics. (A) Mean tumor volume per mouse. FVB N = 32, B6 N = 44. Data are means +/- SEM. (B) Tumor latency for individual B6 PyMT/iNOS+/+ and PyMT/iNOS-/- tumors. Data were derived from examining 460 B6 PyMT/iNOS+/+and 260 PyMT/iNOS-/-tumors
###end p 29
###begin title 30
Deficiency in iNOS-modulated tumor growth is site specific
###end title 30
###begin p 31
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2003</xref>
###xml 141 144 141 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 258 261 258 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 753 756 753 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 770 773 770 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 934 935 934 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 938 944 938 944 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 992 993 992 993 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 1050 1053 1050 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1063 1064 1063 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1075 1076 1075 1076 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 1279 1282 1279 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1290 1291 1290 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1349 1352 1349 1352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1356 1357 1356 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1386 1389 1386 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1393 1394 1393 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 944 1411 944 1411 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Distribution of B6 mammary gland tumor burden. (<bold>A</bold>) Total tumor burden was significantly lower in PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice, ***<italic>P</italic>&#160;&lt;&#160;0.001. (<bold>B</bold>) Examination of individual tumors indicated that a significant difference in genotypes was only found in the #3 and #4 mammary glands, although in each gland the mean tumor burden was lower in PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice. *<italic>P</italic>&#160;&lt;&#160;0.05 ANOVA followed by Bonferroni post tests. PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;24 (black bars), PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;25 (grey bars)</p>
###xml 944 1411 944 1411 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Distribution of B6 mammary gland tumor burden. (<bold>A</bold>) Total tumor burden was significantly lower in PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice, ***<italic>P</italic>&#160;&lt;&#160;0.001. (<bold>B</bold>) Examination of individual tumors indicated that a significant difference in genotypes was only found in the #3 and #4 mammary glands, although in each gland the mean tumor burden was lower in PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice. *<italic>P</italic>&#160;&lt;&#160;0.05 ANOVA followed by Bonferroni post tests. PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;24 (black bars), PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;25 (grey bars)</p></caption>
###xml 1411 1411 1411 1411 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11248_2006_9056_Fig4_HTML" id="MO4"/>
###xml 938 1411 938 1411 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="32">Distribution of B6 mammary gland tumor burden. (<bold>A</bold>) Total tumor burden was significantly lower in PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice, ***<italic>P</italic>&#160;&lt;&#160;0.001. (<bold>B</bold>) Examination of individual tumors indicated that a significant difference in genotypes was only found in the #3 and #4 mammary glands, although in each gland the mean tumor burden was lower in PyMT/iNOS<sup>&#8722;/&#8722;</sup> mice. *<italic>P</italic>&#160;&lt;&#160;0.05 ANOVA followed by Bonferroni post tests. PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;24 (black bars), PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;25 (grey bars)</p></caption><graphic position="anchor" xlink:href="11248_2006_9056_Fig4_HTML" id="MO4"/></fig>
###xml 1411 1418 1411 1418 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1418 1470 1418 1470 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Quantitative analysis of tumor microvascular density</p>
###xml 1418 1470 1418 1470 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Quantitative analysis of tumor microvascular density</p></caption>
###xml 1470 1478 1470 1478 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Genotype</th>
###xml 1478 1486 1478 1486 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Location</th>
###xml 1486 1487 1486 1487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1486 1487 1486 1487 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>N</italic></th>
###xml 1495 1496 1494 1495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1499 1500 1498 1499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1487 1501 1487 1500 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MVD (&#956;m<sup>2</sup>/mm<sup>2</sup>)</th>
###xml 1470 1501 1470 1500 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Genotype</th><th align="left">Location</th><th align="left"><italic>N</italic></th><th align="left">MVD (&#956;m<sup>2</sup>/mm<sup>2</sup>)</th></tr>
###xml 1470 1501 1470 1500 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Genotype</th><th align="left">Location</th><th align="left"><italic>N</italic></th><th align="left">MVD (&#956;m<sup>2</sup>/mm<sup>2</sup>)</th></tr></thead>
###xml 1510 1513 1509 1512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1501 1513 1500 1512 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PyMT/iNOS<sup>+/+</sup></td>
###xml 1513 1515 1512 1514 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">#1</td>
###xml 1515 1516 1514 1515 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9</td>
###xml 1516 1526 1515 1523 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">216&#160;&#177;&#160;20</td>
###xml 1501 1526 1500 1523 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#1</td><td align="left">9</td><td char="&#177;" align="char">216&#160;&#177;&#160;20</td></tr>
###xml 1535 1538 1532 1535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1526 1538 1523 1535 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PyMT/iNOS<sup>+/+</sup></td>
###xml 1538 1542 1535 1539 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">#2&#8211;5</td>
###xml 1542 1543 1539 1540 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9</td>
###xml 1543 1553 1540 1548 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">176&#160;&#177;&#160;12</td>
###xml 1526 1553 1523 1548 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#2&#8211;5</td><td align="left">9</td><td char="&#177;" align="char">176&#160;&#177;&#160;12</td></tr>
###xml 1562 1565 1557 1560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1553 1565 1548 1560 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td>
###xml 1565 1567 1560 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">#1</td>
###xml 1567 1568 1562 1563 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 1568 1578 1563 1571 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">201&#160;&#177;&#160;11</td>
###xml 1553 1578 1548 1571 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#1</td><td align="left">6</td><td char="&#177;" align="char">201&#160;&#177;&#160;11</td></tr>
###xml 1587 1590 1580 1583 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1578 1590 1571 1583 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td>
###xml 1590 1594 1583 1587 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">#2&#8211;5</td>
###xml 1594 1596 1587 1589 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11</td>
###xml 1596 1606 1589 1597 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">189&#160;&#177;&#160;11</td>
###xml 1578 1606 1571 1597 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#2&#8211;5</td><td align="left">11</td><td char="&#177;" align="char">189&#160;&#177;&#160;11</td></tr>
###xml 1501 1606 1500 1597 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#1</td><td align="left">9</td><td char="&#177;" align="char">216&#160;&#177;&#160;20</td></tr><tr><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#2&#8211;5</td><td align="left">9</td><td char="&#177;" align="char">176&#160;&#177;&#160;12</td></tr><tr><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#1</td><td align="left">6</td><td char="&#177;" align="char">201&#160;&#177;&#160;11</td></tr><tr><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#2&#8211;5</td><td align="left">11</td><td char="&#177;" align="char">189&#160;&#177;&#160;11</td></tr></tbody>
###xml 1470 1606 1470 1597 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Genotype</th><th align="left">Location</th><th align="left"><italic>N</italic></th><th align="left">MVD (&#956;m<sup>2</sup>/mm<sup>2</sup>)</th></tr></thead><tbody><tr><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#1</td><td align="left">9</td><td char="&#177;" align="char">216&#160;&#177;&#160;20</td></tr><tr><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#2&#8211;5</td><td align="left">9</td><td char="&#177;" align="char">176&#160;&#177;&#160;12</td></tr><tr><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#1</td><td align="left">6</td><td char="&#177;" align="char">201&#160;&#177;&#160;11</td></tr><tr><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#2&#8211;5</td><td align="left">11</td><td char="&#177;" align="char">189&#160;&#177;&#160;11</td></tr></tbody></table>
###xml 1606 1628 1597 1617 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Data are means&#160;&#177;&#160;SEM</p>
###xml 1606 1628 1597 1617 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Data are means&#160;&#177;&#160;SEM</p></table-wrap-foot>
###xml 1411 1628 1411 1617 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="33">Quantitative analysis of tumor microvascular density</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Genotype</th><th align="left">Location</th><th align="left"><italic>N</italic></th><th align="left">MVD (&#956;m<sup>2</sup>/mm<sup>2</sup>)</th></tr></thead><tbody><tr><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#1</td><td align="left">9</td><td char="&#177;" align="char">216&#160;&#177;&#160;20</td></tr><tr><td align="left">PyMT/iNOS<sup>+/+</sup></td><td align="left">#2&#8211;5</td><td align="left">9</td><td char="&#177;" align="char">176&#160;&#177;&#160;12</td></tr><tr><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#1</td><td align="left">6</td><td char="&#177;" align="char">201&#160;&#177;&#160;11</td></tr><tr><td align="left">PyMT/iNOS<sup>&#8722;/&#8722;</sup></td><td align="left">#2&#8211;5</td><td align="left">11</td><td char="&#177;" align="char">189&#160;&#177;&#160;11</td></tr></tbody></table><table-wrap-foot><p textid="34">Data are means&#160;&#177;&#160;SEM</p></table-wrap-foot></table-wrap>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 1054 1058 <span type="species:ncbi:10090">mice</span>
###xml 1283 1287 <span type="species:ncbi:10090">mice</span>
In concordance with increased tumor latency and decreased tumor growth (Ellies et al. 2003) tumor burden was significantly lower in PyMT/iNOS-/- mice (Fig. 4A). An examination of tumor burden in individual mammary glands revealed a reduction in all PyMT/iNOS-/- glands compared to controls, although the numbers were only significant in the #3 and #4 mammary glands (Fig. 4A). It is interesting to note that these are the glands with the largest fat pads and may indicate a role for the stroma in the iNOS effect. To assess a role for tumor vascularization in this effect we examined tumor microvascular density (MVD) in #1and #2-5 tumors of both genotypes. Although there was a slight reduction in the mean MVD in #1 versus #2-5 tumors in the PyMT/iNOS+/+ and PyMT/iNOS-/- genotypes, it was not statistically significant, suggesting this is not the mechanism for the difference observed in tumor growth at different locations (Table 1). Fig. 4Distribution of B6 mammary gland tumor burden. (A) Total tumor burden was significantly lower in PyMT/iNOS-/- mice, ***P < 0.001. (B) Examination of individual tumors indicated that a significant difference in genotypes was only found in the #3 and #4 mammary glands, although in each gland the mean tumor burden was lower in PyMT/iNOS-/- mice. *P < 0.05 ANOVA followed by Bonferroni post tests. PyMT/iNOS+/+ B6 N = 24 (black bars), PyMT/iNOS-/- B6 N = 25 (grey bars)Table 1Quantitative analysis of tumor microvascular densityGenotypeLocationNMVD (mum2/mm2)PyMT/iNOS+/+#19216 +/- 20PyMT/iNOS+/+#2-59176 +/- 12PyMT/iNOS-/-#16201 +/- 11PyMT/iNOS-/-#2-511189 +/- 11Data are means +/- SEM
###end p 31
###begin p 32
###xml 48 49 48 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 131 132 131 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 335 338 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 405 408 405 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 412 413 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 442 445 442 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 449 450 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
Distribution of B6 mammary gland tumor burden. (A) Total tumor burden was significantly lower in PyMT/iNOS-/- mice, ***P < 0.001. (B) Examination of individual tumors indicated that a significant difference in genotypes was only found in the #3 and #4 mammary glands, although in each gland the mean tumor burden was lower in PyMT/iNOS-/- mice. *P < 0.05 ANOVA followed by Bonferroni post tests. PyMT/iNOS+/+ B6 N = 24 (black bars), PyMT/iNOS-/- B6 N = 25 (grey bars)
###end p 32
###begin p 33
Quantitative analysis of tumor microvascular density
###end p 33
###begin p 34
Data are means +/- SEM
###end p 34
###begin p 35
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 547 553 547 553 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 660 663 660 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 765 768 765 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 553 1067 553 1067 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Tumor latency of individual B6 mammary glands. Tumor latency was lower in the #1 mammary gland in PyMT/iNOS<sup>+/+</sup> mice compared with all other mammary glands (upper panel). A similar result was observed in PyMT/iNOS<sup>+/+</sup> mice, with an increase in disparity between the latency of the #1 gland and all other glands (middle panel). When the #1 and #4 latencies for both genotypes were overlayed, a greater difference in mean tumor latency was observed between the #4 glands when compared with the #1 glands (lower panel) </p>
###xml 553 1067 553 1067 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Tumor latency of individual B6 mammary glands. Tumor latency was lower in the #1 mammary gland in PyMT/iNOS<sup>+/+</sup> mice compared with all other mammary glands (upper panel). A similar result was observed in PyMT/iNOS<sup>+/+</sup> mice, with an increase in disparity between the latency of the #1 gland and all other glands (middle panel). When the #1 and #4 latencies for both genotypes were overlayed, a greater difference in mean tumor latency was observed between the #4 glands when compared with the #1 glands (lower panel) </p></caption>
###xml 1067 1067 1067 1067 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11248_2006_9056_Fig5_HTML" id="MO5"/>
###xml 547 1067 547 1067 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="36">Tumor latency of individual B6 mammary glands. Tumor latency was lower in the #1 mammary gland in PyMT/iNOS<sup>+/+</sup> mice compared with all other mammary glands (upper panel). A similar result was observed in PyMT/iNOS<sup>+/+</sup> mice, with an increase in disparity between the latency of the #1 gland and all other glands (middle panel). When the #1 and #4 latencies for both genotypes were overlayed, a greater difference in mean tumor latency was observed between the #4 glands when compared with the #1 glands (lower panel) </p></caption><graphic position="anchor" xlink:href="11248_2006_9056_Fig5_HTML" id="MO5"/></fig>
###xml 664 668 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
This site-specific effect prompted us to examine tumor latency in individual glands. We had observed during palpations that the #1 mammary gland was usually the first to develop tumors, however we were surprised to find a clear difference between the latency of the #1 tumors compared with all other tumors (Fig. 5). This difference was more noticeable in the absence of iNOS. The greater difference in mean latency in the #4 glands compared with the #1 glands was consistent with the tumor burden results being more significant in the #4 glands. Fig. 5Tumor latency of individual B6 mammary glands. Tumor latency was lower in the #1 mammary gland in PyMT/iNOS+/+ mice compared with all other mammary glands (upper panel). A similar result was observed in PyMT/iNOS+/+ mice, with an increase in disparity between the latency of the #1 gland and all other glands (middle panel). When the #1 and #4 latencies for both genotypes were overlayed, a greater difference in mean tumor latency was observed between the #4 glands when compared with the #1 glands (lower panel)
###end p 35
###begin p 36
###xml 107 110 107 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 216 220 <span type="species:ncbi:10090">mice</span>
Tumor latency of individual B6 mammary glands. Tumor latency was lower in the #1 mammary gland in PyMT/iNOS+/+ mice compared with all other mammary glands (upper panel). A similar result was observed in PyMT/iNOS+/+ mice, with an increase in disparity between the latency of the #1 gland and all other glands (middle panel). When the #1 and #4 latencies for both genotypes were overlayed, a greater difference in mean tumor latency was observed between the #4 glands when compared with the #1 glands (lower panel)
###end p 36
###begin title 37
iNOS effects on tumor metastasis
###end title 37
###begin p 38
###xml 322 325 322 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 339 342 339 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 352 353 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 525 528 525 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 719 725 719 725 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 744 745 744 745 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 797 800 797 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 827 830 827 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 853 854 853 854 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 914 915 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 936 937 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 953 956 953 956 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 961 962 961 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 978 981 978 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 986 987 986 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1003 1006 1003 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1010 1011 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 1027 1030 1027 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1034 1035 1034 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 725 1040 725 1040 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Tumor metastasis. (<bold>A</bold>) HE stained paraffin embedded sections of PyMT/iNOS<sup>+/+</sup> (left panel) and PyMT/iNOS<sup>&#8722;/&#8722;</sup> (right panel) lungs. (<bold>B</bold>) Comparison of metastatic tumor burden in FVB and B6 mice *<italic>P</italic>&#160;&lt;&#160;0.05 Mann-Whitney <italic>U</italic> test. PyMT/iNOS<sup>+/+</sup> FVB <italic>N</italic>&#160;=&#160;14, PyMT/iNOS<sup>&#8722;/&#8722;</sup> FVB <italic>N</italic>&#160;=&#160;13, PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;17, PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;21</p>
###xml 725 1040 725 1040 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Tumor metastasis. (<bold>A</bold>) HE stained paraffin embedded sections of PyMT/iNOS<sup>+/+</sup> (left panel) and PyMT/iNOS<sup>&#8722;/&#8722;</sup> (right panel) lungs. (<bold>B</bold>) Comparison of metastatic tumor burden in FVB and B6 mice *<italic>P</italic>&#160;&lt;&#160;0.05 Mann-Whitney <italic>U</italic> test. PyMT/iNOS<sup>+/+</sup> FVB <italic>N</italic>&#160;=&#160;14, PyMT/iNOS<sup>&#8722;/&#8722;</sup> FVB <italic>N</italic>&#160;=&#160;13, PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;17, PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;21</p></caption>
###xml 1040 1040 1040 1040 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11248_2006_9056_Fig6_HTML" id="MO6"/>
###xml 719 1040 719 1040 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="39">Tumor metastasis. (<bold>A</bold>) HE stained paraffin embedded sections of PyMT/iNOS<sup>+/+</sup> (left panel) and PyMT/iNOS<sup>&#8722;/&#8722;</sup> (right panel) lungs. (<bold>B</bold>) Comparison of metastatic tumor burden in FVB and B6 mice *<italic>P</italic>&#160;&lt;&#160;0.05 Mann-Whitney <italic>U</italic> test. PyMT/iNOS<sup>+/+</sup> FVB <italic>N</italic>&#160;=&#160;14, PyMT/iNOS<sup>&#8722;/&#8722;</sup> FVB <italic>N</italic>&#160;=&#160;13, PyMT/iNOS<sup>+/+</sup> B6 <italic>N</italic>&#160;=&#160;17, PyMT/iNOS<sup>&#8722;/&#8722;</sup> B6 <italic>N</italic>&#160;=&#160;21</p></caption><graphic position="anchor" xlink:href="11248_2006_9056_Fig6_HTML" id="MO6"/></fig>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 529 533 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
###xml 908 912 <span type="species:ncbi:10090">mice</span>
The PyMT model has been useful for the study of tumor metastasis due to the high penetrance of this clinically important characteristic of tumor progression. However, we found that in the FVB strain, tumors were so aggressive that no significant difference could be observed in the metastatic burden occurring in PyMT/iNOS+/+ and PyMT/iNOS-/- mice Fig 6. Although the incidence of tumor metastasis was less in the B6 strain, a statistically significant difference between the genotypes was found. We have maintained PyMT/iNOS-/- mice for up to 32 weeks and found no increase in metastatic burden (data not shown), suggesting that the decrease in metastasis is not due simply to the delayed tumor latency in these mice. Fig. 6Tumor metastasis. (A) HE stained paraffin embedded sections of PyMT/iNOS+/+ (left panel) and PyMT/iNOS-/- (right panel) lungs. (B) Comparison of metastatic tumor burden in FVB and B6 mice *P < 0.05 Mann-Whitney U test. PyMT/iNOS+/+ FVB N = 14, PyMT/iNOS-/- FVB N = 13, PyMT/iNOS+/+ B6 N = 17, PyMT/iNOS-/- B6 N = 21
###end p 38
###begin p 39
###xml 19 20 19 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 102 105 102 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 128 129 128 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 189 190 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 228 231 228 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 236 237 236 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 253 256 253 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 278 281 278 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 285 286 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 302 305 302 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 309 310 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
Tumor metastasis. (A) HE stained paraffin embedded sections of PyMT/iNOS+/+ (left panel) and PyMT/iNOS-/- (right panel) lungs. (B) Comparison of metastatic tumor burden in FVB and B6 mice *P < 0.05 Mann-Whitney U test. PyMT/iNOS+/+ FVB N = 14, PyMT/iNOS-/- FVB N = 13, PyMT/iNOS+/+ B6 N = 17, PyMT/iNOS-/- B6 N = 21
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2003</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2001</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
Mouse models of mammary tumorigenesis have provided important insights into the molecular basis of human breast cancer and are essential for gathering preclinical data regarding therapeutic drug efficacy. The PyMT model in the FVB strain has a mean tumor latency of 53 days and has been used extensively in studies of mammary tumorigenesis (Cardiff 2003; Muller and Neville 2001). The model is frequently crossed with gene-targeted strains that have been generated in the B6/129 mixed background or backcrossed onto the B6 background. We had highly variable results examining iNOS effects in a mixed B6/FVB PyMT background and sought to characterize the phenotype of this mutation in congenic FVB and B6 strains. Our study demonstrates that the genetic background of the PyMT model can affect the ability to discern differences in phenotype due to genetic alterations that require time to influence tumor progression. Differences observed in the B6 background were obscured in the FVB background due to the signficantly shorter tumor latency and more rapid tumor growth in this strain.
###end p 41
###begin p 42
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2005</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">1998</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">1991</xref>
###xml 748 752 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2002</xref>
###xml 886 890 886 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2005</xref>
###xml 1112 1116 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2005</xref>
###xml 1136 1140 <span type="species:ncbi:10090">mice</span>
Further analysis of mammary tumorigenesis in the B6 background indicated that tumor formation occurred in 2 phases: early, from 12-17 weeks and late, from 19-23 weeks. It is the early phase of tumor formation that is most affected in the absence of iNOS, consistent with recent data linking iNOS expression with transcriptional upregulation of signal transducers and activators of transcription 3 (STAT3) by nuclear epidermal growth factor receptor (EGFR) (Lo et al. 2005). EGFR/ErbB1, a member of the ErbB family of receptor tyrosine kinases that signal via the same pathways as PyMT (Webster et al. 1998), is also found in the nucleus of highly proliferative cells where is functions as a transcription factor (Marti et al. 1991; Wells and Marti 2002). Structural and functional characterization of the iNOS promoter has identified binding elements for both EGFR and STAT3 (Lo et al. 2005). Immunohistochemical studies of breast carcinomas show that nuclear EGFR positively correlates with iNOS and survival analysis demonstrates that high levels of iNOS are a prognostic indicator of poor survival (Lo et al. 2005). Thus the B6 PyMT mice in the presence or absence of iNOS deficiency are likely to provide an important model for further analysis of these novel molecular interactions.
###end p 42
###begin p 43
###xml 1193 1197 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">1985</xref>
###xml 1215 1219 1215 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1998</xref>
###xml 42 48 <span type="species:ncbi:10090">murine</span>
###xml 1092 1097 <span type="species:ncbi:10090">mouse</span>
Mammary tumor latency for each of the ten murine mammary glands has generally been assumed to be stoichiometric. However our data demonstrate that the #1 mammary glands have tumor initiating properties that are distinct from the other 4 pairs of mammary glands. The #1 mammary glands have the smallest fat pads and are located in the head and neck region, which is highly vascular, so we hypothesized that an increase in vascular density in the #1 tumors could be responsible for this difference. An examination of the microvacular density (MVD) of #1 tumors versus all others showed a trend in which #1 tumors had a higher mean MVD than #2-5 tumors as determined by quantitative analysis of CD31 staining. However, these values were not statistically significant, suggesting a different mechanism is responsible for the observed site-specific differences in tumor burden and tumor latency. Other factors in the stromal microevironment may also play a role in mediating this effect. The release of epidermal growth factor (EGF) from the submandibular salivary gland has been shown to promote mouse mammary tumorigenesis in virus mediated and chemical carcinogen induced models (Kurachi et al. 1985; Molinolo et al. 1998). The proximity of the #1 glands to the submandibular gland make EGF induced proliferation a plausible explanation, however further investigations will be required to determine whether the release of this growth factor primarily affects the #1 glands.
###end p 43
###begin p 44
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2004</xref>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2002</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2004</xref>
###xml 712 716 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2006</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2002</xref>
###xml 845 849 845 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2006</xref>
Another possible explanation for this intriguing difference is that the #1 mammary gland is developmentally distinct from the other mammary glands. The #1 gland is not the first to develop since placode 3 develops first at E11.0-11.5 on the ectodermal streak between the forelimb and hindlimb (Eblaghie et al. 2004; Mailleux et al. 2002). Placodes 1 and 5 arise from the axillary and inguinal streaks respectively and placodes 4 and 2 form where the mammary line abuts these streaks (Veltmaat et al. 2004). Recent studies indicate that signaling molecules essential for mammogenesis are placode dependent. Placodes 2 and 3 do not form in the absence of Lef1 mediated canonical Wnt signaling (Boras-Granic et al. 2006) and placodes 1, 2, 3 and 5 require Fgf10 signaling from somites underlying the ectoderm (Mailleux et al. 2002; Veltmaat et al. 2006). It is clear there are developmental differences between mammary glands and it is possible that early developmental factors result in an increased propensity for malignant transformation in the #1 mammary glands, though the identity of these factors remains to be determined.
###end p 44
###begin p 45
###xml 245 248 245 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 335 338 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 511 514 511 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2003</xref>
###xml 71 78 <span type="species:ncbi:9606">patient</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
Since metastasis is an aspect of tumor progression that is critical to patient survival, we examined the effect of iNOS on tumor metastasis in both the FVB and B6 backgrounds. No significant difference in metastatic burden was found in PyMT/iNOS-/- mice in the FVB background, however the tumor burden was reduced in lungs of PyMT/iNOS-/- mice in the B6 background compared with controls. Furthermore, the reduction in metastatic burden was not due simply to the delayed tumor latency as we maintained PyMT/iNOS-/- mice longer to compensate for the difference and found that this did not alter our previous findings (Ellies et al. 2003).
###end p 45
###begin p 46
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2005</xref>
###xml 262 266 262 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2005</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2001</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Human clinical studies have associated increased iNOS expression with poor prognosis in breast cancer patients (Loibl et al. 2005), and the use of non-steroidal anti-inflammatory drugs (NSAIDs) with a 22-39% reduction in the risk of breast cancer (Harris et al. 2005; Khuder and Mutgi 2001). To increase our understanding of the molecular pathways involved in these effects, it is essential to have animal models that recapitulate the clinical findings. We have shown that in the PyMT B6 background loss of iNOS, an important inflammatory mediator, results in increased tumor latency and decreased tumor metastasis that is not due simply to the difference in latency. This model will be useful in determining molecular pathways underlying the role of iNOS in breast cancer.
###end p 46
###begin title 47
Acknowledgements
###end title 47
###begin p 48
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Drs. Ajit Varki and Lubor Borsig provided the PyMT mice in the C57Bl/6J background. The authors thank the UCSD Cancer Center Histology and Immunohistochemistry Shared Resource for technical assistance. This work was supported by NIH R01-CA81376. L.G.E. was supported by NCI grant K08-CA88035. J.E.M. was a Susan G. Komen Fellow.
###end p 48
###begin title 49
References
###end title 49
###begin article-title 50
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland
###end article-title 50
###begin article-title 51
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 16 21 <span type="species:ncbi:9606">human</span>
Mouse models of human breast cancer
###end article-title 51
###begin article-title 52
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 39 44 <span type="species:ncbi:10090">mouse</span>
The comparative pathology of human and mouse mammary glands
###end article-title 52
###begin article-title 53
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
Interactions between FGF and Wnt signals and Tbx3 gene expression in mammary gland initiation in mouse embryos
###end article-title 53
###begin article-title 54
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase
###end article-title 54
###begin article-title 55
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
Interrogating mouse mammary cancer models: insights from gene expression profiling
###end article-title 55
###begin article-title 56
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Polyoma tumorigenesis in mice: evidence for dominant resistance and dominant susceptibility genes of the host
###end article-title 56
###begin article-title 57
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease
###end article-title 57
###begin article-title 58
###xml 91 106 <span type="species:ncbi:10090">transgenic mice</span>
Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice
###end article-title 58
###begin article-title 59
Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade
###end article-title 59
###begin article-title 60
Breast cancer and NSAID use: a meta-analysis
###end article-title 60
###begin article-title 61
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
Evidence for the involvement of the submandibular gland epidermal growth factor in mouse mammary tumorigenesis
###end article-title 61
###begin article-title 62
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death
###end article-title 62
###begin article-title 63
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Prevention of virus-induced neoplasms in mice through passive transfer of immunity by sensitized syngeneic lymphoid cells
###end article-title 63
###begin article-title 64
An epistatic interaction controls the latency of a transgene-induced mammary tumor
###end article-title 64
###begin article-title 65
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression
###end article-title 65
###begin article-title 66
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy
###end article-title 66
###begin article-title 67
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
###end article-title 67
###begin article-title 68
###xml 67 72 <span type="species:ncbi:9606">human</span>
The role of early expression of inducible nitric oxide synthase in human breast cancer
###end article-title 68
###begin article-title 69
###xml 28 33 <span type="species:ncbi:9606">human</span>
Gene expression profiles of human breast cancer progression
###end article-title 69
###begin article-title 70
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo
###end article-title 70
###begin article-title 71
Localization of epidermal growth factor receptor in hepatocyte nuclei
###end article-title 71
###begin article-title 72
###xml 143 147 <span type="species:ncbi:10090">mice</span>
Involvement of EGF in medroxyprogesterone acetate (MPA)-induced mammary gland hyperplasia and its role in MPA-induced mammary tumors in BALB/c mice
###end article-title 72
###begin article-title 73
Introduction: Signaling in mammary development and tumorigenesis
###end article-title 73
###begin article-title 74
###xml 72 76 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 82 97 <span type="species:ncbi:10090">transgenic mice</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease
###end article-title 74
###begin article-title 75
A molecular signature of metastasis in primary solid tumors
###end article-title 75
###begin article-title 76
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors
###end article-title 76
###begin article-title 77
The role of thymus in transplantation resistance induced by polyoma virus
###end article-title 77
###begin article-title 78
Gli3-mediated somitic Fgf10 expression gradients are required for the induction and patterning of mammary epithelium along the embryonic axes
###end article-title 78
###begin article-title 79
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
Identification of the mammary line in mouse by Wnt10b expression
###end article-title 79
###begin article-title 80
Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis
###end article-title 80
###begin article-title 81
Signalling shortcuts: cell-surface receptors in the nucleus?
###end article-title 81
###begin article-title 82
Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion
###end article-title 82
###begin title 83
Abbreviations
###end title 83
###begin p 84
inducible nitric oxide synthase
###end p 84
###begin p 85
polyomavirus middle T antigen
###end p 85

